Kallyope
is a New York-based biotechnology company that researches and develops small-molecule therapies to treat metabolic, gastrointestinal and neurological disorders... Read moreKallyope
is a New York-based biotechnology company that researches and develops small-molecule therapies to treat metabolic, gastrointestinal and neurological disorders... Read more
News
Jan 07, 2026
StreetInsider
Press Release: Kallyope : Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platform
Dec 18, 2025
Yahoo
Kallyope: Kallyope To Present at the 44th Annual J.P. Morgan Healthcare Conference
Dec 09, 2025
Clinical Trials Arena
Kallyope: Kallyope's migraine drug advances to pivotal trial
Dec 08, 2025
StreetInsider
Press Release: Kallyope : Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine
Feb 27, 2025
Endpoints News
Kallyope: Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial
Sep 10, 2024
Business Wire
Press Release: Kallyope : Kallyope Announces License Agreement with Novo Nordisk
Nov 10, 2023
Outsourcing-Pharma
Kallyope: Sosei Heptares and Kallyope collaboration milestone with first GPCR target
Sep 26, 2023
Acrofan
Kallyope: Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes
May 11, 2023
Citybizlist
Kallyope: Kallyope Receives $8.2 Million Grant from Gates Foundation
Aug 05, 2022
Citybizlist
Kallyope: Renowned Biopharma Leaders Join Kallyope Clinical Development Advisory Board
Kallyope Competitors
1
2
3
4
5
6
7
8
9
10